1. ¹Immunisation Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
2. ²Modelling and Economics Unit, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
3. ³Vaccine Evaluation Unit, Health Protection Agency North West Laboratory, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester M13 9WZ, UK
4. ⁴HIV & STI Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK

Correspondence: Dr M Jit, E-mail: mark.jit@hpa.org.uk

Received 19 June 2007; Revised 3 August 2007; Accepted 3 August 2007; Published online 28 August 2007.

Abstract

Sera from 1483 female subjects in England aged 10–29 years were tested. The age-standardised seroprevalence was 10.7% (95% confidence intervals 9.0–12.3) for human papillomavirus (HPV) 6, 2.7% (1.8–3.6) for HPV 11, 11.9% (10.2–13.6) for HPV 16, 4.7% (3.5–5.8) for HPV 18, and 20.7% (18.6–22.7) for any of the four types.